We kicked off the start of our ongoing livestreams with the announcement of Psymposia's 501(c)(3) non-profit status, discussions of corporadelic dynamics, fond memories of helping people learn how to extract psychedelic drugs during an Ivy League University's psychedelic conference, and a whole bunch of back and forth with the audience about the current state (and future) of psychedelia.

Jamon A. Rahn, CEO of psychedelic pharmaceutical startup MindMed, offered a glimpse of the future of psychedelic science, including proprietary data and hints of an “LSD neutralizer.”

What is it about psychedelics that has the power to change lives for the better? The answer might lie in the unique ways that psychedelics interact with the brain.

I hypnotized some of the attendees and put them on cocaine, pot, beer, and even ecstasy. I interviewed them afterwards and asked them if it felt real. And each of them said yes. Quite real. Then my head exploded.

After the murder of a Peruvian healer in 2018, traditional healers, local political figures, and nonprofit allies gathered to address the complexities that come with the influx of foreigners seeking ayahuasca in the Amazon.

Conspiracy theories are nothing new when it comes to psychedelia. But in the context of coronavirus, they've become significantly more harmful.

As psychedelic medicalization and the potential profits of a “virgin market” loom large, new organizations are increasingly looking to gain legitimacy within the field. Mainstreaming means the doors of this field are being thrown wide open.

What does MDMA rescheduling mean for the recreational user? If you are under the impression that MDMA is on its way to being rescheduled, across the board, you may be disappointed.

The Multidisciplinary Association for Psychedelic Studies (MAPS) submitted their MDMA PTSD expanded access protocol to the FDA on January 14, 2019.

UC Berkeley SSDP members are organizing college classes focused on drug education.